Paul Fonteyne's Insider Trades & SAST Disclosures
Paul Fonteyne's most recent trade in Apellis Pharmaceuticals Inc was a trade of 11,199 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Paul Fonteyne.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 11,199 | 11,199 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 6,267 | 22,705 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Apellis Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 5,748 | 5,748 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Fonteyne Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 3,341 | 16,438 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 16,985 | 16,985 | - | - | Stock Option (right to buy) | |
| Apellis Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 7,441 | 7,441 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 3,867 | 13,097 (0%) | 0% | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 8,400 | 8,400 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharmaceuticals Inc | Paul Fonteyne | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Jan 2022 | 3,947 | 3,947 | - | 19 | 74,993 | Common Stock |
| Apellis Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 8,554 | 8,554 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 4,230 | 9,230 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Paul Fonteyne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2021 | 27,600 | 27,600 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges